Pressmeddelanden från Curasight

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Notice of Annual General Meeting 2026 06 mar 18:26

Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade 26 feb 08:05

Annual Report 2025 26 feb 08:00

Year-end report Q4 2025 17 feb 06:59

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston 09 feb 17:16

Major Shareholding Notification 12 jan 18:00

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas 05 jan 10:30

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week 29 dec 2025 13:18

Curasight A/S resolves to issue a convertible loan note 29 dec 2025 10:31

Resolutions of the Extraordinary General Meeting December 2025 18 dec 2025 17:19

Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer 14 dec 2025 17:34

Notice of Extraordinary General Meeting 12 dec 2025 22:37

Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility 12 dec 2025 18:38

Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility 28 nov 2025 11:09

Curasight to present at HC Andersen Capital 27 nov 2025 07:00

Interim report Q3 2025 26 nov 2025 07:11

Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment 13 nov 2025 08:23

Curasight to present at Dansk Aktionærforening InvestorDagen 29 okt 2025 08:10

Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting 01 okt 2025 07:00

Curasight announces broadening and extension of patent protection for uTRACE®03 sep 2025 21:51

Transaction with shares in Curasight A/S made by managerial employee 28 aug 2025 07:00

Half-year report Q2 2025 26 aug 2025 07:05

Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients 23 jun 2025 17:35

Curasight A/S announces outcome of T03 warrant exercise 18 jun 2025 17:35

Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients 03 jun 2025 17:45

The exercise period commences for warrants of series TO3 on 4 June 2025 02 jun 2025 08:15

Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue 28 maj 2025 17:25

Completed registration of rights issue 28 maj 2025 14:26

Resolutions of the Annual General Meeting 2025 of Curasight A/S 21 maj 2025 08:14

Curasight announces outcome in rights issue 15 maj 2025 16:09

Subscription of new shares in the Right Issue 2025 exercised by Curasight management 13 maj 2025 17:14

Notice of Annual General Meeting 2025 13 maj 2025 08:46

Last day of the subscription period in Curasight’s rights issue of shares 07 maj 2025 08:06

Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer 06 maj 2025 14:28

BioStock: Curasight’s rights issue subscription period has commenced 06 maj 2025 14:28

BioStock: Teckningsperioden för Curasights företrädesemission har inletts 02 maj 2025 07:30

THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY 30 apr 2025 12:17

Curasight to present at HC Andersen Capital 29 apr 2025 22:22

Curasight A/S publishes disclosure document regarding rights issue 25 apr 2025 08:47

Annual Report for the fiscal year 2024 25 apr 2025 08:25

Interim report Q1 2025 24 apr 2025 08:30

CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE 23 apr 2025 11:38

Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025 11 apr 2025 08:26

BioStock: Curasight strengthens the investor base with Curium and Pentwater 11 apr 2025 08:26

BioStock: Curasight stärker investerarbasen med Curium och Pentwater 08 apr 2025 20:42

Notice of Extraordinary General Meeting of Curasight A/S 04 apr 2025 17:14

Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million 26 mar 2025 07:00

Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025 28 feb 2025 08:07

BioStock: Curasight caps 2024 with financing push 27 feb 2025 07:00

Year-end report Q4 2024 05 feb 2025 09:24

Curasight announces an updated financial calendar 2025 10 dec 2024 19:05

Participation in warrant exercise by Curasight management 10 dec 2024 07:22

Curasight A/S announces outcome of warrant exercise 02 dec 2024 08:10

SEB maintain valuation range midpoint at DKK 54 per share 02 dec 2024 07:00

The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 26 nov 2024 08:45

BioStock: Curasights vd reflekterar över starkt Q3 26 nov 2024 08:45

BioStock: Curasight CEO reflects on a Q3 with strong progress 22 nov 2024 08:25

Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]21 nov 2024 07:55

The exercise period for warrants of series TO2 commences today 21 nov 2024 07:00

Interim report Q3 2024 20 nov 2024 08:10

The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share 15 nov 2024 08:45

BioStock: Curasight announces brain cancer as initial target for uTREAT 15 nov 2024 08:45

BioStock: Curasight väljer hjärncancer som första indikation för uTREAT 14 nov 2024 07:00

Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference 13 nov 2024 07:05

Curasight announces international patent application for uTREAT® to broaden IP protection 11 nov 2024 11:00

Curasight presenterar på BioStock Life Science Summit 21 november 11 nov 2024 11:00

Curasight will present at the BioStock Life Science Summit, November 21 11 nov 2024 07:00

Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 08 nov 2024 14:25

BioStock: Full phase II results of uPAR-PET in glioblastoma published 08 nov 2024 14:25

BioStock: Fullständiga fas II-resultat med uPAR-PET i glioblastom publicerade 08 nov 2024 10:42

Curasight to present at Dansk Aktionærforening InvestorDagen 07 nov 2024 07:00

Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer 22 okt 2024 08:45

BioStock: Curasight well-placed in hot radiopharma sector 22 okt 2024 08:45

BioStock: Curasight väl positionerat inom het radiofarmakasektor 11 okt 2024 13:19

Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3 03 okt 2024 08:41

Curasight A/S rights issue heavily oversubscribed 16 sep 2024 08:50

Commencement of subscription period in Curasight’s preferential rights issue 12 sep 2024 12:22

Curasight A/S publishes prospectus due to upcoming rights issue 10 sep 2024 08:15

BioStock: Curasight carries out the first step of capitalization 10 sep 2024 08:15

BioStock: Curasight genomför första steget i kapitalanskaffning 04 sep 2024 09:25

The Board of Directors resolves on a directed issue of units and preferential rights issue of units 29 aug 2024 08:15

BioStock: Curasight siktar på kliniskt proof-of-concept för uTREAT 29 aug 2024 08:15

BioStock: Curasight targets clinical proof-of-concept for uTREAT 22 aug 2024 07:00

Interim report Q2 2024 30 jul 2024 10:39

Curasight issues warrants as part of long-term incentive program 02 jul 2024 14:11

Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024 01 jul 2024 11:53

Directed issues registered at the Danish Business Authority 25 jun 2024 09:15

BioStock: Curasights vd kommenterar kapitalanskaffning och milstolpe 25 jun 2024 09:15

BioStock: Curasight CEO comments on capital raise and milestone 22 jun 2024 11:22

Curasight to present at HC Andersen Capital 17 jun 2024 16:05

Notice of Extraordinary General Meeting 14 jun 2024 17:22

Curasight A/S resolves on directed issues and a loan facility 12 jun 2024 07:11

Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer 04 jun 2024 08:45

BioStock: Curasight committed to progressing pipeline 04 jun 2024 08:45

BioStock: Curasight tar nästa steg i utvecklingen av pipelinen 23 maj 2024 07:00

Interim report Q1 2024 22 apr 2024 08:45

BioStock: Curasight får grönt ljus från EMA för fas II prostatacancerstudie 22 apr 2024 08:45

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial 16 apr 2024 20:39

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients 12 apr 2024 11:58

Curasight announces change in the Board of Directors